{"id":"W2089842133","doi":"10.1158/1535-7163.targ-09-c49","title":"Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non-toxic in a preclinical model of advanced triple negative breast cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Aptose Biosciences (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nimotuzumab; Medicine; Metastatic breast cancer; Panitumumab; Cetuximab; Triple-negative breast cancer; Cyclophosphamide; Breast cancer; Cancer; Bevacizumab; Docetaxel; Trastuzumab; Oncology; Combination therapy; Cancer research; Targeted therapy; Pharmacology; Monoclonal antibody; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Immunology; Antibody; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001650681,0.0004597258,0.0006375888,0.0003509317,0.0001764372,0.0002553558,0.0003313892,0.0003958968,0.001608299],"category_scores_gemma":[0.0001135235,0.0001257866,0.0002659091,0.00017953,0.0001928942,0.0001675698,0.0001138264,0.0007611042,0.0003487184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000426023,"about_ca_system_score_gemma":0.0005726467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00176716,"about_ca_topic_score_gemma":0.003541701,"domain_scores_codex":[0.9998277,0.00002439618,0.00001094334,0.00002845543,0.00005276182,0.00005563148],"domain_scores_gemma":[0.9998968,0.00001097897,0.00001981666,0.00001048034,0.0000133684,0.00004858753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003345027,0.002872776,0.0002683089,0.00006638564,0.00003596234,0.00009694861,0.00002196062,0.0004641626,0.9854957,0.0001328432,0.0006599821,0.006539877],"study_design_scores_gemma":[0.0009950541,0.03841865,0.004935783,0.00001251699,0.00009182416,0.0004117428,0.00002339827,0.002666214,0.9475146,0.00004792172,0.004866667,0.00001567906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955382,0.0007899511,0.0007813408,0.0001350531,0.0001066109,0.000189281,0.000580414,0.00008810973,0.001791053],"genre_scores_gemma":[0.9929379,0.0006712183,0.001721989,0.00006919339,0.00003962226,0.000191967,0.0009869884,0.00002407244,0.003357166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00176716,"threshold_uncertainty_score":0.005380332,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03126555443784302,"score_gpt":0.3740643119938047,"score_spread":0.3427987575559617,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}